Why receptor reserve matters for neurokinin1 (NK1) receptor antagonists

References

• Stephenson RP. A modification of receptor theory. Br J Pharmacol 1956;11:379–3
   PubMed Web of Science ®Google Scholar
• Black JW, Leff P. Operational models of pharmacological agonism. Proc R Soc Lond B 1983;220:141–62
   PubMed Web of Science ®Google Scholar
• Furchgott RF. The use of β-haloalkylamines in the differentiation of receptors and in the determination of dissociation constants of receptor-agonist complexes. In: Harper NJ, Simmonds AB, eds. Advances in drug research. London: Academic Press; 1966, 21–55
   Google Scholar
• Kenakin TP. Receptor reserve as a tissue misnomer. Trends Pharmacol Sci 1986;7:93–5
   Web of Science ®Google Scholar
• Ebner K, Sartori SB, Singewald N. Tachykinin receptors as therapeutic targets in stress-related disorders. Curr Pharm Design 2009;15:1647–74
   PubMed Web of Science ®Google Scholar
• Holmes A, Heilig M, Rupniak N, et al. Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends Pharmacol Sci 2003;24:580–8
   PubMed Web of Science ®Google Scholar
• Brocco M, Dekeyne A, Mannoury la Cour C, et al. Cellular and behavioural profile of the novel, selective neurokinin1 receptor antagonist, vestipitant: a comparison to other agents. Eur Neuropsychopharmacol 2008;18:729–50
   PubMedGoogle Scholar
• Di Fabio R, Griffante C, Alvaro G, et al. Discovery process and pharmacological characterization of 2-(S)-(4-Fluoro-2-methylphenyl)piperazine-1-carboxylic Acid [1-(R)-(3,5-bis trifluoromethylphenyl)ethyl]methylamide (Vestipitant) as a potent, selective, and orally active NK1 receptor antagonist. J Med Chem 2009;52:3238–47
   Google Scholar
• Di Fabio R, Alvaro G, Griffante C, et al. Discovery and biological characterization of (2R,4S)-10-acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,40-bipiperidine-1-carboxamide as a new potent and selective neurokinin 1 (NK1) receptor antagonist clinical candidate. J Med Chem 2011;54:1071–9
   Google Scholar
• Ratti E, Bellew K, Bettica P, et al. Results from 2 randomized. double-blind, placebo-controlled studies of the novel nk1 receptor antagonist casopitant in patients with major depressive disorder. J Clin Psychopharmacol 2011;31:727–33
   PubMed Web of Science ®Google Scholar
• Kramer MS, Cutler N, Feighner J, et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998;28:1640–5
   Google Scholar
• Keller M, Montgomery S, Ball W, et al. Lack of efficacy of the substance P (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol Psychiatry 2006;59:216–23
   PubMed Web of Science ®Google Scholar
• Kramer MS, Winokur A, Kelsey J, et al. Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology 2004;29:385–92
   PubMed Web of Science ®Google Scholar
• Chappell P. Effects of CP-122,721, a selective NK-1 receptor antagonist, in patients with MDD. Presented at NCDEU June 12, 2002 (referenced in McLean, S. Do substance P and the NK1 receptor have a role in depression and anxiety)? Curr Pharm Des 2005;11:1529–47
   Google Scholar
• Ratti E, Bettica P, Alexander R, et al. Full central NK1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studies. J Psychopharmacol 2013;27:424–34
   Google Scholar
• GSK Clinical Study Register. 2003. NK20006 – an 8-week, randomized, double-blind, placebo-controlled, multicenter, fixed-dose study comparing the efficacy and safety of a new chemical entity (NCE) or paroxetine to placebo in moderately to severely depressed patients with major depressive disorder. Available from: http://www.gsk-clinicalstudyregister.com/result_comp_list.jsp?compound=vestipitant [last accessed 30 Sep 2013]
   Google Scholar
• Zamuner S, Rabiner EA, Fernandes SA, et al. A pharmacokinetic PET study of NK1 receptor occupancy. Eur J Nucl Med Mol Imaging 2012;39:226–35
   Google Scholar
• Carletti R, Griffante C, Pozzato C, et al. NK1 receptor occupancy and anxiolytic-like effect of the novel NK1 receptor antagonist Vestipitant (GW597599) in gerbil. Eur Neuropsychopharmacol 2005;15:S533–9
   Google Scholar
• GSK Clinical Study Register. 2009. NKI111364 – a 28-day, polysomnographic and subjective assessment of vestipitant (15 mg/day) for the treatment of primary insomnia in adult outpatients. Available from: http://www.gsk-clinicalstudyregister.com/result_comp_list.jsp?compound=vestipitant [last accessed 30 Sep 2013]
   Google Scholar
• GSK Clinical Study Register. 2006. GW679769/903 – a randomized, double-blind, placebo-controlled, cross-over study to evaluate the effects of GW679769 (30 mg and 90 mg) on sleep continuity, PSG sleep recordings, subjective sleep assessment, and daytime cognitive function in subjects with primary insomnia. Available from: http://www.gsk-clinicalstudyregister.com/result_comp_list.jsp?compound=casopitant [last accessed 30 Sep 2013]
   Google Scholar
• Arai H, Emson PC. Regional distribution of neuropeptide K and other tachykinins (neurokinin A, neurokinin B and substance P) in rat central nervous system. Brain Res 1986;399:240–9
   PubMed Web of Science ®Google Scholar
• Gobbi G, Blier P. Effect of neurokinin-1 receptor antagonists on serotoninergic, noradrenergic and hippocampal neurons: comparison with antidepressant drugs. Peptides 2005;26:1383–93
   PubMed Web of Science ®Google Scholar
• Gobbi G, Cassano T, Radja F, et al. Neurokinin 1 receptor antagonism requires norepinephrine to increase serotonin function. Eur Neuropsychopharmacol 2007;17:328–38
   Google Scholar
• Haddjeri N, Blier P. Sustained blockade of neurokinin-1 receptors enhances serotonin neurotransmission. Biol Psychiatry 2001;50:191–9
   PubMedGoogle Scholar
• Gobert A, Brocco M, Dekeyne A, et al. Neurokinin-1 antagonists potentiate antidepressant properties of serotonin reuptake inhibitors, yet blunt their anxiogenic actions: a neurochemical, electrophysiological, and behavioral characterization. Neuropsychopharmacology 2009;34:1039–56
   Google Scholar
• Bondy B, Baghai TC, Minov C, et al. Substance P serum levels are increased in major depression: preliminary results. Biol Psychiatry 2003;53:538–42
   PubMed Web of Science ®Google Scholar
• Geracioti TD Jr, Carpenter LL, Owens MJ, et al. Elevated cerebrospinal fluid substance P concentrations in posttraumatic stress disorder and major depression. Am J Psychiatry 2006;163:637–43
   PubMed Web of Science ®Google Scholar
• Yocca FD, Iben L, Meller E. Lack of apparent receptor reserve at postsynaptic 5-hydroxytryptamine 1A receptors negatively coupled to adenylyl cyclase activity in rat hippocampal membranes. Mol Pharmacol 1992;41:1066–72
   PubMed Web of Science ®Google Scholar
• Ebner K, Singewald GM, Whittle N, et al. Neurokinin 1 receptor antagonism promotes active stress coping via enhanced septal 5-HT transmission. Neuropsychopharmacology 2008;33:1929–41
   Google Scholar
• Kalia M. Neurobiology of sleep. Metabol Clin Exp 2006;55:S2–6
   Web of Science ®Google Scholar